Probio-M9
Tislelizumab
Seventh Medical Center of PLA General HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Tislelizumab cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab Sichuan Cancer Hospital and Research Institute | Phase 2 | B |
LENVATINIB Qilu Hospital of Shandong University | Phase 2 | B |
rc48-adc Sichuan Cancer Hospital and Research Institute | Phase 2 | B |
Pyrotinib Sichuan Cancer Hospital and Research Institute | Phase 2 | B |
Docetaxel Sun Yat-sen University | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Probio-M9 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →